Readers' Comments on "Reassessing Smoore: Mistakes, Crisis, and the Way Forward"

Industry Insight by 2FIRSTS
Jan.04.2024
Readers' Comments on "Reassessing Smoore: Mistakes, Crisis, and the Way Forward"
2FIRSTS released an article titled "Reassessing Smoore: Mistakes, Crisis, and the Way Forward", sparking widespread discussion in the e-cigarette industry.

On January 3rd, 2FIRSTS published an in-depth article titled "Rethinking Smoore: Mistakes, crisis, and a way forward". The article immediately sparked widespread discussion within the e-cigarette industry.

 

2FIRSTS has conducted a comprehensive summary of various perspectives on the Smoore issue thus far. The aim is to provide readers with a more comprehensive viewpoint for further contemplation and discussion.

 

Below are the various perspectives: 

 

@migao: 

 

The missed opportunity in the disposable business and the late push with two major clients are closely related. Smoore mainly operates as an OEM business, meaning that no matter how great its technology is, it is in vain if customers do not utilize it. This inherent passivity in Smoore's role explains why it fell behind in the disposable market. Had BAT positioned themselves earlier in the disposable market, Smoore would have naturally kept up. After all, the technology required for disposable products is relatively low, and Smoore already possessed accumulated enough to meet the product demands.

 

Speculating further, it can be said that the tobacco industry in the UK and the US is not as quick to embrace disposables, not because they are unaware of the trend but rather because they are cautious about entering into cutthroat competition. Up until 2022, they may have held on to the hope that disposables would not gain popularity, considering the significant profit gap compared to pod-based systems. However, they eventually realized that they couldn't ignore the trend and had to personally engage in the market. Losing market share is more terrifying than sacrificing profits.

 

Therefore, based on the aforementioned points, it is not surprising that Smoore's lagging behind in the market carries a certain degree of expected sorrow.

 

The game of major client and the demand for optimizing supply chain costs for major clients have been clearly reflected in the past year in British American Tobacco and RELX. This year, British American Tobacco has placed 50% or even more of its disposable business with FirstUnion. Although they have introduced multiple new products this year, the main existing models and a new flagship model are now dominated by FirstUnion. This directly led to Smoore's failure to achieve its target of 4 billion in disposable business at the beginning of the year. If it had not been transferred to FirstUnion, Smoore's disposable business this year would have been around 50-60, but I estimate it will be around 35. RELX also experienced a similar situation, where the domestic market shifted from being solely supplied by Smoore to being shared by Smoore, FirstUnion, and ALD. As for the overseas market, I do not have the data, but I conservatively estimate that Smoore now accounts for less than 40%.

 

@Keepupthegoodwork:

 

The entire article fails to mention Smoore's compliance issues, such as PMTA, which is the fundamental reason why it has not entered the US market. In the European market, disposable companies have violated TPD rules by entering with a large number of products, which is also a significant reason why Smoore has not collaborated with these companies. Therefore, Smoore's current situation is largely due to various policy reasons, not its research and development efforts. Additionally, it should be noted that half of Smoore's research and development investment is allocated to HNB products, not solely disposable products, which the articles have failed to mention.

 

@999Roses:

 

In my impression, this seems to be the most detailed article analyzing Smoore. After reading it several times, I feel both disappointed by the setback of a giant and reassured by glimpses of hope. I am someone who believes in the power of time and believes in the order of the world. The road for e-cigarettes is still very long. The market will eventually move away from prioritizing growth data. At that time, the ultimate winner will be the one with the safest product and sufficient trust. There is a saying in the business world, "Don't compare who has a more glamorous life, but who can live longer." Yes, I believe Smoore is the company that will always be at the table.

 

Anonymous user:

 

Smoore has missed out on the best period of overseas development, which is both a strategic misjudgment and a result of their difficulty in ignoring external regulations. They are a company with long-term plans and have not made any fundamental mistakes in major decisions. However, China and overseas markets are two different playing fields, and therefore require two different approaches. Nevertheless, Smoore has once flourished, but it now appears increasingly quiet in the face of external capital speculation.

 

Anonymous User:

 

Smoore's investment is long-term and represents recognition of the regulatory trends surrounding e-cigarette compliance and the regulation of similar tobacco products. Due to requirements for compliance as a public company, Smoore cannot dramatically increase production orders. Additionally, as the tobacco industry is dominated by a few key players, Smoore must maintain strong relationships with these market leaders. In the short term, the e-cigarette market is not yet in a highly regulated era, so Smoore's second growth phase will not occur just yet. As a technology-driven company, Smoore must focus on iterating and innovating its vaporization technology, controlling factory costs, and betting on its new vaporization technology consumer products becoming popular. However, it is still too early to say whether these strategies will be successful.

 

It is even uncertain whether Smoore will remain standing until the day the mist clears.

 

An User on Xueqiu:

 

The analysis is sound, but it is unclear whether the author intentionally or unintentionally overlooked an important point - the importance of compliance and the impact of strong regulation on competition. RELX and Smoore's success was achieved in an environment without stringent regulation, which proved their capabilities as a manufacturer and brand. However, in the later years, the industry faced strong regulation, which noticeably affected major players like RELX and Smoore. On the other hand, new small and medium-sized manufacturers could take advantage of regulatory loopholes for penetration and development of new products, without facing the same restrictions. As a result, RELX and Smoore found themselves constrained within a very limited space, making the competition unequal. The decline in their market share, apart from not keeping up with e-cigarette consumer trends, can largely be attributed to this unfair competition. However, running fast doesn't guarantee running far. From a regulatory standpoint, e-cigarettes are burdened with "original sin." Therefore, compliance with regulations, legality, and ESG (Environmental, Social, and Governance) initiatives are the basic guarantees for companies to persist in the long run. RELX and Smoore possess much stronger capabilities in these aspects compared to other new players, although this often goes unnoticed.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
Ireland’s Vape Tax Raises €22 Million in Nine Months as Government Considers 2027 Budget Changes
According to Irish media outlets Highland Radio and BreakingNews.ie, the Irish government is considering whether to adjust vape tax policy in the 2027 Budget. The tax has generated about €22 million ($24 million) in revenue during its first nine months. While no increase has been confirmed, the revenue performance could influence future fiscal discussions. Any tax rise could increase product costs and potentially affect retail prices.
Aug.12
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
EU Tobacco Tax Reform Targets November Push as Sweden Holds Nicotine-Pouch Minimum at €20 per Kilogram
The Irish presidency of the Council of the European Union is using bilateral talks to push the bloc’s Tobacco Taxation Directive toward a political agreement in November. According to Law360, citing an EU official, Sweden is unwilling to accept a minimum excise threshold above €20 per kilogram for nicotine pouches. Council negotiations have already lowered the European Commission’s original proposal, but a May 2026 presidency compromise still set the minimum at 10% of the tax-inclusive retail price or €30 per kilogram in 2028-29, with higher levels later.
Market
Sep.17 by 2Firsts Perspectives
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13